Activity Details

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

• Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
• Select appropriate therapy for patients with CML refractory to 2^nd generation agents
• Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must:

• Review and successfully complete the activity
• Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

• Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
• Select appropriate therapy for patients with CML refractory to 2^nd generation agents
• Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must:

• Review and successfully complete the activity
• Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Accredited By

Target Audience

This activity is intended for administrative and clinical professionals (hematologists, general internists, advanced practice professionals, social workers) seeking to develop adult comprehensive care programs at their institutions.

Learning Objective

Upon completion of this course, the participants should be able to:

• Outline approaches to optimal clinical care for patients with Sickle Cell Disease (SCD)

Activity Description

There are many new therapies for sickle cell disease. Understanding how they work and where they work is crucial to managing patients. Dr. Julie Kanter explains the latest approved therapies and invites you to demonstrate your knowledge through interactive games.

Agenda

• Pathophysiology of Sickle Cell Disease
• Clinical manifestations and complications of SCD
• Novel therapies in SCD
• Curative therapies

Activity Faculty

Julie Kanter, MD
SCD Centers Workshop Co-Director
Associate Professor, Division of Hematology & Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

Steering Committee Faculty

Payal Desai, MD
Director of Sickle Cell Research
Co-Director of Sickle Cell Program
The Ohio State University
Columbus, Ohio

Sophie Lanzkron, MD
SCD Centers Workshop Co-Director
Associate Professor of Medicine and Oncology, Division of Hematology
Director, Sickle Cell Center for Adults
Johns Hopkins Medicine
Baltimore, Maryland

Wally R. Smith, MD
SCD Centers Workshop Co-Director
Florence Neal Cooper Smith Professor of Sickle Cell Disease
Vice Chairman for Research, Division of General Internal Medicine
Virginia Commonwealth University
Richmond, Virginia

Conflict of Interest Policy/Disclosure Statement

The France Foundation participated in the development of this activity in collaboration with The American Society of Hematology. In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society of Hematology (ASH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

The following staff at TFF report that they have relevant financial relationships to disclose:

• Patrick Harty, PhD, reports that his spouse is employed by Pfizer, Inc. and they hold stock in Pfizer, Inc.

The planners, reviewers, editors, staff, CME committee, or other members at ASH who control content have no relevant financial relationships to disclose.

The faculty listed below report that they have no relevant financial relationships to disclose:

• Dr. Desai does consulting for Accel Pharma and serves on the speakers bureau for Novartis. She does contract research for Global Blood Therapeutics and UPMC. Dr. Desai is also writing a publication for Pfizer, Inc.
• Dr. Kanter does consulting for Axcella Health, Gerson Lehrman Group, Graphite, Guidepoint Global, Imara, Novartis, and Wells Fargo. She also serves on advisory boards for Acel Rx, Agios, Astrazeneca, Beam Therapeutics, Forma Therapeutics, Novartis, Novo Nordisk, Sanofi, and Sancillo.
• Dr. Lanzkron does consulting for bluebird bio, Novo Nordisk, and Pfizer, Inc. She is a site primary investigator for contract research for Imara, Shire, and Novartis. Dr. Lanzkron also owns stock in Pfizer, Inc. and Teva Pharmaceuticals.
• Dr. Smith does consulting for GBT, GMI, Novartis, and Pfizer, Inc. He also does contract research for GBT, Imara, Novartis, and Shire.

Accreditation Statement

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
ASH designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The America Society of Hematology, an ACCME accredited provider.

Method of Participation/How to Receive Credit

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CME/CE information.
3. Complete the CME/CE activity.
4. Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
   • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
   • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by educational grants from bluebird bio, Forma Therapeutics, Global Blood Therapeutics, and Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and ASH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

The France Foundation and the American Society of Hematology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASH, and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Accredited By

Target Audience

This activity is intended for administrative and clinical professionals (hematologists, general internists, advanced practice professionals, social workers) seeking to develop adult comprehensive care programs at their institutions.

Learning Objective

Upon completion of this course, the participants should be able to:

• Outline approaches to optimal clinical care for patients with Sickle Cell Disease (SCD)

Activity Description

There are many new therapies for sickle cell disease. Understanding how they work and where they work is crucial to managing patients. Dr. Julie Kanter explains the latest approved therapies and invites you to demonstrate your knowledge through interactive games.

Agenda

• Pathophysiology of Sickle Cell Disease
• Clinical manifestations and complications of SCD
• Novel therapies in SCD
• Curative therapies

Activity Faculty

Julie Kanter, MD
SCD Centers Workshop Co-Director
Associate Professor, Division of Hematology & Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

Steering Committee Faculty

Payal Desai, MD
Director of Sickle Cell Research
Co-Director of Sickle Cell Program
The Ohio State University
Columbus, Ohio

Sophie Lanzkron, MD
SCD Centers Workshop Co-Director
Associate Professor of Medicine and Oncology, Division of Hematology
Director, Sickle Cell Center for Adults
Johns Hopkins Medicine
Baltimore, Maryland

Wally R. Smith, MD
SCD Centers Workshop Co-Director
Florence Neal Cooper Smith Professor of Sickle Cell Disease
Vice Chairman for Research, Division of General Internal Medicine
Virginia Commonwealth University
Richmond, Virginia

Conflict of Interest Policy/Disclosure Statement

The France Foundation participated in the development of this activity in collaboration with The American Society of Hematology. In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society of Hematology (ASH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

The following staff at TFF report that they have relevant financial relationships to disclose:

• Patrick Harty, PhD, reports that his spouse is employed by Pfizer, Inc. and they hold stock in Pfizer, Inc.

The planners, reviewers, editors, staff, CME committee, or other members at ASH who control content have no relevant financial relationships to disclose.

The faculty listed below report that they have no relevant financial relationships to disclose:

• Dr. Desai does consulting for Accel Pharma and serves on the speakers bureau for Novartis. She does contract research for Global Blood Therapeutics and UPMC. Dr. Desai is also writing a publication for Pfizer, Inc.
• Dr. Kanter does consulting for Axcella Health, Gerson Lehrman Group, Graphite, Guidepoint Global, Imara, Novartis, and Wells Fargo. She also serves on advisory boards for Acel Rx, Agios, Astrazeneca, Beam Therapeutics, Forma Therapeutics, Novartis, Novo Nordisk, Sanofi, and Sancillo.
• Dr. Lanzkron does consulting for bluebird bio, Novo Nordisk, and Pfizer, Inc. She is a site primary investigator for contract research for Imara, Shire, and Novartis. Dr. Lanzkron also owns stock in Pfizer, Inc. and Teva Pharmaceuticals.
• Dr. Smith does consulting for GBT, GMI, Novartis, and Pfizer, Inc. He also does contract research for GBT, Imara, Novartis, and Shire.

Accreditation Statement

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
ASH designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The America Society of Hematology, an ACCME accredited provider.

Method of Participation/How to Receive Credit

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CME/CE information.
3. Complete the CME/CE activity.
4. Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
   • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
   • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by educational grants from bluebird bio, Forma Therapeutics, Global Blood Therapeutics, and Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and ASH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

The France Foundation and the American Society of Hematology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASH, and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

1. Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
2. Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
3. Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.

The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.

Faculty

Jeffrey V. Matous, MD
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO

Conflict of Interest Policy/Disclosure Statement

Research Grant: Pharmacyclics
Consultant: Pharmacyclics

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

1. Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
2. Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
3. Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.

The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.

Faculty

Jeffrey V. Matous, MD
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO

Conflict of Interest Policy/Disclosure Statement

Research Grant: Pharmacyclics
Consultant: Pharmacyclics

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

• Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
• Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
• Describe case scenarios in which maintenance therapy may become standard in the near future
• Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

• Read the learning objectives and faculty disclosures
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

Activity Details

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

• Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
• Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
• Describe case scenarios in which maintenance therapy may become standard in the near future
• Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

• Read the learning objectives and faculty disclosures
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.